Sight Sciences Q3 revenue $19.9M, raises FY25 guidance; promotes COO and CFO

Sight Sciences, Inc.

2025-Q3 EPS reported -$0.66 revenue$56,978,000

Surgical Glaucoma revenue $19.7M (+6% YoY); Dry Eye revenue $0.2M (-88%) as company focuses on reimbursed access.
Net loss narrowed to $8.2M ($0.16 loss per share) from $11.1M loss in Q3 2024.
Raises FY2025 revenue guidance to $76-78M (from $72-76M); reduces adj. op. expense guidance to $90-92M.
Promoted Alison Bauerlein to COO from CFO, James Rodberg to CFO, effective Nov 5, 2025.
Board members Becker and Rogers resigned; board size reduced from 9 to 7.

item 2.02item 5.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.